Spinal health depends on the dynamic interplay between mechanical forces, biochemical signaling, and cellular behavior. This review explores how key molecular pathways, including integrin, yeas-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), Piezo, and Wingless/Integrated (Wnt) with β-catenin, actively shape the structural and functional integrity of spinal tissues. These signaling mechanisms respond to physical cues and interact with inflammatory mediators such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α), driving changes that lead to disc degeneration, vertebral fractures, spinal cord injury, and ligament failure. New research is emerging that shows scaffold designs that can directly harness these pathways. Further, new stem cell-based therapies have been shown to promote disc regeneration through targeted differentiation and paracrine signaling. Interestingly, many novel bone and ligament scaffolds are modulating anti-inflammatory signals to enhance tissue repair and integration, as well as prevent scaffold degradation. Neural scaffolds are also arising. These mimic spinal biomechanics and activate Piezo signaling to guide axonal growth and restore motor function. Scientists have begun combining these biological platforms with brain–computer interface technology to restore movement and sensory feedback in patients with severe spinal damage. Although this technology is not fully clinically ready, this field is advancing rapidly. As implantable technology can now mimic physiological processes, molecular signaling, biomechanical design, and neurotechnology opens new possibilities for restoring spinal function and improving the quality of life for individuals with spinal disorders.

Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF) pathway inhibitors are increasingly used in bone and soft tissue sarcomas. Risks associated with combination therapy, such as venous thromboembolism (VTE), carry significant consequences but remain poorly characterized. This study evaluated whether adding a VEGF pathway inhibitor to ICI therapy increases VTE risk in sarcoma patients. Using the TriNetX U.S. Collaborative Network, we identified patients with bone or soft tissue sarcoma [International Classification of Diseases (ICD)-10 C40, C41, C47, C49] who received either combination therapy (ICI plus VEGF pathway inhibitor within ±30 days of ICI initiation) or ICI monotherapy. Propensity score matching (1:1) balanced cohorts for age, sex, race, hypertension, diabetes, obesity, and smoking history. The primary outcome was 1-year VTE incidence (pulmonary embolism or venous thrombosis). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. After matching, 834 patients remained in each cohort (mean age 63 years; hypertension prevalence 60%). At 1 year, VTE occurred in 14.0% of the combination cohort and 12.4% of the monotherapy cohort (HR 1.23; 95% CI: 0.91-1.66; P=0.07), corresponding to an absolute risk difference of 1.6 percentage points (95% CI: -2.1 to 5.2). Musculoskeletal toxicity did not differ between groups (5.5% vs. 6.4%; HR 0.93; 95% CI: 0.61-1.41; P=0.82). Sarcoma patients receiving ICI-based therapy experienced a high 1-year VTE burden. Although we did not detect a statistically significant increase in VTE with the addition of a VEGF pathway inhibitor, the point estimates were compatible with a modestly higher risk; however, the CIs were wide and included no difference between groups. These findings support clinical vigilance and risk assessment and motivate prospective studies of risk-adapted thromboprophylaxis in this population.